

FULLY DEVELOPED		
Product Name	CAS Number	Main Therapeutic Indication
Celecoxib	[169590-42-5]	Antiarthritic Drug
Ciclopirox	[29342-05-0]	Antifungal
Ciclopirox Olamine	[41621-49-2]	Antifungal
Citicoline Monosodium Salt	[33818-15-4]	Treatment of neurological and cognitive disorders
Cobamamide	[13870-90-13]	Appetite Stimulant
Hydroxocobalamin Acetate	[22465-48-1]	Vitamin B12 deficiency including pernicious anemia
Hydroxocobalamin Hydrochloride	[58288-50-9]	Vitamin B12 deficiency including pernicious anemia
Hydroxocobalamin Sulphate	[13422-51-0]	Vitamin B12 deficiency including pernicious anemia
Imiquimod	[99011-02-6]	Basal Cell Carcinoma; Genital Warts Therapy
Mecobalamin	[13422-55-4]	Peripheral neuropathies and Megaloblastic anemia caused by vitamin B12 deficiency
Olmesartan Medoxomil	[144689-63-4]	Antihypertensive
Paliperidone	[144598-75-4]	Antipsychotic Drug
Paliperidone Palmitate	[199739-10-1]	Antipsychotic Drug
Ranolazine	[95635-55-5]	Treatment of Chronic Angina Pectoris
Rasagiline Tartrate	[136236-52-7]	Antiparkinson Drug
Risperidone	[106266-06-2]	Antipsychotic Drug
Rivaroxaban	[366789-02-8]	Anticoagulant
Rivastigmine	[123441-03-2]	Treatment of Alzheimer's Dementia
Rivastigmine Tartrate	[129101-54-8]	Treatment of Alzheimer's Dementia
Roflumilast	[162401-32-3]	Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Rotigotine	[99755-59-6]	Antiparkinson Drug
Sertaconazole Nitrate	[99592-39-9]	Vulvovaginal candidiasis

Note: Products protected by a patent are developed exclusively for the purpose stated in article 10.6 of the Directive 2001/83/EC as amended by the Directive 2004/27/EC. No activity will be performed with products protected by a patent in force in Spain beyond the scope of article 52.1, b) of the Spanish Patent Act and, in particular, these products will not be offered or supplied but only for obtaining marketing authorization for generic medicines in Spain or out of Spain. None of the products will be offered for sale or supply to countries in which they were affected by a patent in force.

Solifenacin Succinate	[242478-38-2]	Urinary Incontinence Therapy
Tadalafil	[171596-29-5]	Erectile Dysfunction; Pulmonary Arterial Hypertension
Telmisartan	[144701-48-4]	Antihypertensive
Tolterodine Tartrate	[124937-52-6]	Urinary Incontinence Therapy
Torasemide	[56211-40-6]	Diuretic, Treatment of Hypertension
UTP Trisodium Salt	[19817-92-6]	Treatment of neuropathological conditions of osteoarticular metabolic and infectious origins

Note: Products protected by a patent are developed exclusively for the purpose stated in article 10.6 of the Directive 2001/83/EC as amended by the Directive 2004/27/EC. No activity will be performed with products protected by a patent in force in Spain beyond the scope of article 52.1, b) of the Spanish Patent Act and, in particular, these products will not be offered or supplied but only for obtaining marketing authorization for generic medicines in Spain or out of Spain. None of the products will be offered for sale or supply to countries in which they were affected by a patent in force.

UNDER DEVELOPMENT		
Product Name	CAS Number	Main Therapeutic Indication
Aripiprazole (sterile grade)	[129722-12-9]	Antipsychotic
Aripiprazole lauroxil	[1259305-29-7]	Schizophrenia
Deracoxib	[169590-41-4]	Control of pain and inflammation associated with osteoarthritis in dogs
Ferric Carboxymaltose	[9007-72-1]	Iron Deficiency Anemia
Lifitegrast	[1025967-78-5]	Dry eye syndrome
Mirabegron	[223673-61-8]	Urinary Incontinence Therapy
Pimavanserin tartrate	[706782-28-7]	Induced psychosis in patients with parkinson disease
Sucroferric Oxyhydroxide	[12134-57-5]	Control of serum phosphorous levels

Note: Products protected by a patent are developed exclusively for the purpose stated in article 10.6 of the Directive 2001/83/EC as amended by the Directive 2004/27/EC. No activity will be performed with products protected by a patent in force in Spain beyond the scope of article 52.1, b) of the Spanish Patent Act and, in particular, these products will not be offered or supplied but only for obtaining marketing authorization for generic medicines in Spain or out of Spain. None of the products will be offered for sale or supply to countries in which they were affected by a patent in force.